Linda A.Hesse

Partner

Paris + 33.1.56.59.38.72

Linda Hesse advises clients in the areas of capital markets, securities law, public M&A, and corporate governance under both U.S. and French law. She acts for issuers with respect to their issuances of debt and equity securities; listings on Euronext, Nasdaq, and the NYSE; and on regulatory matters involving the SEC and the French AMF. Linda also advises financial institutions as advisors in offerings of equity, debt, and complex instruments. She is head of the Paris Office's Capital Markets Practice.

Notable issuer clients include Orange for ongoing securities compliance, debt and equity offerings, and M&A; Sanofi on its ongoing SEC compliance and U.S. shelf program, including its $7 billion Yankee bond in connection with its Genzyme acquisition; EDAP TMS on ongoing securities compliance and equity offerings; and Stallergenes Greer on French securities law matters.

Investment bank clients include BNP Paribas, Crédit Agricole CIB, Natixis, and SVB Leerink. Notable underwriter engagements include representing the underwriters on Genfit's Nasdaq IPO (with respect to French law), Medincell's IPO on Euronext Paris, and Sequans' NYSE IPO.

Linda also advises companies on cross-border public M&A transactions, including Panalpina on its planned acquisition by DSV; Stallergenes Greer in connection with the acquisition of minority shareholders by Waypoint; Kildare Partners on its acquisition of Technopolis Plc; Safran on its acquisition of Zodiac Aerospace; Total on its investment in Clean Energy Fuels; Orange on the Jazztel acquisition; and Stallergenes on the Greer Laboratories merger.

Linda is a member of the International Bar Association and active in the Securities Law Committee.

Experience

  • Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc complete IPO of BoostheatJones Day advised Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc, as joint global coordinators, joint lead managers, and joint bookrunners, in connection with the initial public offering of Boostheat SA, a designer, developer, and producer of technologically advanced, energy efficient, and sustainable heating solutions, on the regulated market of Euronext in Paris.
  • CARMAT completes €60 million reserved offering for specialized and strategic investorsJones Day advised CARMAT SA, a designer and developer of the world's most advanced heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, in connection with its €60 million (US$66.3 million) share capital increase, reserved for investors, specialists of the healthcare and life sciences industry, or strategic partners of CARMAT.
  • Panalpina and DSV join forces by way of CHF 4.6 billion (US$4.6 billion) public exchange of stockJones Day advised Panalpina Welttransport (Holding) AG, Basel, Switzerland, one of the world's leading freight forwarders, with respect to German, EU, and U.S. securities law aspects and foreign direct investment filings in connection with the combination with DSV A/S, Hedhusene, Denmark, by way of a CHF 4.6 billion (US$4.6 billion) public exchange offer of DSV to all Panalpina shareholders to tender their Panalpina shares (listed at SIX Swiss Exchange) against DSV shares (listed at NASDAQ Copenhagen).
  • Syndicate of leading banks complete €715 million share capital increase by Tikehau CapitalJones Day advised Berenberg, Credit Suisse, Natixis, BNP Paribas, Crédit Agricole Corporate and Investment Bank, and Société Générale, as global coordinators, joint lead managers and joint bookrunners, and Citigroup and RBC Capital Markets, as joint lead managers and joint bookrunners, in connection with the €715 million share capital increase without shareholders' preferential subscription rights and with a priority subscription period for existing shareholders by Tikehau Capital, an asset management and investment group.
  • Stallergenes Greer plc acquired by Waypoint for approximately €110 million (US$124 million)Jones Day advised Stallergenes Greer plc in the recommended cash acquisition by Ares Life Sciences I S.à r.l. (Waypoint) of the entire issued, and to be issued, ordinary share capital of Stallergenes Greer not held directly or indirectly by Waypoint by way of a scheme of arrangement for approximately €110 million (US$124 million).
  • SVB Leerink, Barclays, Bryan Garnier, and Natixis underwrite $155.4 million Nasdaq IPO by GenfitJones Day acted as French counsel to the underwriters, led by SVB Leerink and Barclays, as global coordinators, and Bryan Garnier and Natixis, as European bookrunners, in connection with the initial public offering of Genfit S.A., a French Euronext Paris-listed biotechnology company on Nasdaq for a total aggregate amount of $155.4 million, after full exercise of the over-allotment option.
  • Athyrium Capital Management partially issues second tranche of bond issueJones Day advised Athyrium Capital Management, LP in connection with the partial issuance of the second tranche of its bond issue.
  • Kildare Partners enters into negotiated tender offer for all outstanding shares of Technopolis PlcJones Day, as U.S. securities counsel, advised a real estate fund managed by Kildare Partners in connection with the negotiated tender offer for all of the outstanding shares of Technopolis Plc, a Finnish company that provides flexible offices and coworking spaces in 17 campuses across six countries in the Nordic and Baltic Sea region.
  • Bryan Garnier & Co Ltd and Crédit Agricole Corporate and Investment Bank complete €30 million IPO on Euronext by MedinCellJones Day represented Bryan Garnier & Co Ltd and Crédit Agricole Corporate and Investment Bank, as joint global coordinators and joint bookrunners, in connection with the €30 million (US$34.4 million) initial public offering of Ordinary Shares on the regulated market of Euronext in Paris by MedinCell, a developer of next generation of best-in-class medicine.
  • Sanofi completes $2 billion bond issue in U.S. public offeringJones Day represented Sanofi, a global biopharmaceutical company, in its U.S. public offering of $2 billion of notes in two fixed rate tranches.
  • Total invests in Clean Energy Fuels Corp.Jones Day represented Total S.A., a French multinational integrated oil and gas company, in connection with its purchase of 25 percent of Clean Energy Fuels Corp., a leading provider of natural gas fuel and renewable natural gas fuel for transportation in North America, for $83.4 million, and the credit support to be provided by Total of up to $100 million.
  • Cellectis completes $164 million follow-on public offering of American Depositary Shares on NASDAQJones Day represented Cellectis S.A., a French clinical-stage biopharmaceutical developer of innovative cancer treatments using gene editing technologies, in connection with a $164 million public offering of American Depositary Shares on NASDAQ, underwritten by Goldman Sachs & Co. LLC, Citigroup, and Barclays.
  • Athyrium Capital Management refinances Biom'Up's existing debt, finances production and marketing of HEMOBLAST™ Bellows, and completes bond financingJones Day represented Athyrium Capital Management in connection with the refinancing of Biom'Up's existing debt, financing of the production and marketing of its flagship product HEMOBLAST™ Bellows in the United States and the European Union, and the financing of its external growth.
  • Vivendi sells stake in Ubisoft Entertainment for approximately €2 billionJones Day advised Crédit Agricole Corporate and Investment Bank (CACIB) in connection with the sale by Vivendi of its stake in Ubisoft Entertainment (Ubisoft) for approximately €2 billion.
  • Talend completes $188.4 million secondary offering of American Depositary Shares on NASDAQ by Selling ShareholdersJones Day represented Talend SA, a French global leader in cloud and big data integration software, in connection with the $188.4 million secondary public offering of American Depositary (each representing one of its ordinary shares) on NASDAQ, by investment funds affiliated with Silver Lake Sumeru and investment funds affiliated with Balderton Capital.
  • Mainstay Medical International completes €30.1 million issue of shares to new and existing shareholdersJones Day advised Mainstay Medical International plc, an Irish medical device company listed on Euronext Paris and the ESM of the Irish Stock Exchange, in connection with its €30.1 million (US$37.1 million) financing through the issue of shares to new and existing shareholders, primarily institutions in Europe and North America, including the Ireland Strategic Investment Fund (ISIF).
  • Safran completes €8.7 billion agreed tender offer targeting Zodiac Aerospace's shares creating global leader in aircraft equipmentJones Day represented Safran in connection with its €8.7 billion agreed tender offer targeting Zodiac Aerospace's shares to create a global leader in aircraft equipment.
  • Orocobre Limited secures AUD$361 million funding through private placement and underwritten accelerated entitlement offerJones Day represented Orocobre Limited, a leading lithium chemicals producer, in connection with its AUD$361 million capital raising, comprising of a AUD$282 million private placement to Toyota Tsusho Corporation and an underwritten entitlement offer raising AUD$79 million.
  • CARMAT completes €52.9 million capital increaseJones Day represented CARMAT SA, a designer and developer of the world's most advanced heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, in connection with its €52.9 million (US$62.3 million) capital increase implemented without shareholders’ preferential subscription rights by way of a public offering and with a priority subscription period, on an irreducible basis only, to existing shareholders.
  • BNP Paribas, KBC Bank, Société Générale, and ABN AMRO BANK act as initial dealers on Ghelamco’s establishment of new €250 million EMTN Programme and issuance of new Notes for €101.6 millionJones Day advised BNP Paribas Fortis SA/NV and KBC Bank NV, as arrangers, and BNP Paribas Fortis SA/NV, KBC Bank NV, Société Générale, and ABN AMRO BANK, as initial dealers, in connection with the establishment of a new €250 million EMTN Programme of Ghelamco Invest NV guaranteed by Ghelamco Group COMM. VA.
  • Speaking Engagements

    • September 12, 2019
      Sustainable Economy: A Global View
    • 15 novembre 2017
      Biotech/Medtech, comment se financer aux États-Unis?
    • November 15, 2017
      Biotech/Medtech, how to raise funds in United States?
    • October 23, 2017
      Seminar for Listed Companies: What You Need to Know About Recent Legal Developments
    • 17 octobre 2017
      Enquêtes internes vs. Enquêtes judiciaires : les liaisons dangereuses ?
    • September 13, 2017
      ECM Round Table: Market Trends and Landmark Deals 2017, Organized by the Magazine des Affaires, Paris
    • 13 septembre 2017
      Table ronde Equity Capital Markets (ECM) : Tendances et opérations emblématiques 2017 – Organisée par le Magazine des Affaires, Paris
    • 20 avril 2017
      Finale de la 3ème édition du Prix Jones Day/ESSEC/Paris II
    • November 9, 2016
      Jones Day Global Life Sciences Conference – 2016 Issues & Trends
    • 7 janvier 2015
      U.S. IPOs : How and Why
    • 13 novembre 2014
      The ABA's 15th Annual "Live from the SEC"
    • October 6, 2014
      BioM-Forum: IPO in the US - a reality
    • 22 septembre 2014
      4ème Dîner-Débat "HEC au Féminin"
    • February 14, 2013
      European Banking – On the Road to Union and Harmonization?
    • Jeudi 17 janvier 2013
      Introduction en bourse aux Etats-Unis et le JOBS Act : enjeux et problématiques
    • September 20, 2012
      SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
    • 20 septembre 2012
      Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
    • June 30, 2011
      Managing Your Risk - Bribery, Corruption and Business Ethics
    • 23 mai 2011
      Les femmes et le private equity : les nouvelles frontières de la région Moyen-Orient/Afrique du Nord, Séminaire organisé par Venture Catalyst Private Equity Partners avec le soutien de MENA-OCDE Women’s Business Forum, du MENA-OCDE Investment Programme, du Département d’Etat et du Département du Commerce des Etats-Unis
    • May 23, 2011
      Women in Private Equity: New Frontiers for the MENA Region
    • 2 mai 2011
      S’informer et échanger pour mieux administrer - Dîner-débat organisé par HEC au Féminin
    • May 2011
      Managing your Risk - Bribery, Corruption and Business Ethics
    • 27 janvier 2011
      Opérations de Spin-off - enjeux et modalités juridiques : La mise en oeuvre des opérations de spin-off, 2ème volet
    • 9 décembre 2010
      Opérations de Spin-off - enjeux et modalités juridiques : Enjeux réglementaires et opportunités, 1er volet
    • 4 juillet 2007
      Les prises de contrôle rampantes, Association des Juristes de Sciences Po
    • July 4, 2007
      Les prises de contrôle rampantes, Association des Juristes de Sciences Po
    • 3 avril 2007
      Introductions en bourse : feuille de route pratique
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.